Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

FRAmework-01 | Now Enrolling A Ph3 trial evaluating a FRα-targeting ADC in patients with ovarian cancer. Key details: - Enrolling PSOC and PROC - All FRα expression levels - Allows prior mirvetuximab 👇 Click below for trial and enrollment details

LillyOncMed's profile picture

Lilly Oncology Medical

6,550 subscribers

2,675,562 görüntüleme • 3 ay önce •via X (Twitter)

Sağlık & İyilikHaberler & PolitikaBilim & Teknoloji
LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: clinical.request@ocugen.com #OCU410ST #Ocugen
1:02

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: [email protected] #OCU410ST #Ocugen

Ocugen

13,591 görüntüleme • 7 ay önce

PM-JAY is literally a lifesaver! It's a policy that is a game-changer for cancer patients. Enrolling in this program is accelerating cancer treatment across India. Kudos on launching this incredible initiative! #AyushmanKiShaktiCancerSeMukti #WorldCancerDay PMO India Narendra Modi
0:44

PM-JAY is literally a lifesaver! It's a policy that is a game-changer for cancer patients. Enrolling in this program is accelerating cancer treatment across India. Kudos on launching this incredible initiative! #AyushmanKiShaktiCancerSeMukti #WorldCancerDay PMO India Narendra Modi

Emraan Hashmi

45,200 görüntüleme • 1 yıl önce

The ECLIPSE Trial has completed enrollment with the randomization of 2000 patients. Dr. Philippe Généreux and I discuss the design of the trial in which vessel preparation strategies are compared in severely calcified coronary artery lesions.
9:06

The ECLIPSE Trial has completed enrollment with the randomization of 2000 patients. Dr. Philippe Généreux and I discuss the design of the trial in which vessel preparation strategies are compared in severely calcified coronary artery lesions.

C. Michael Gibson MD

15,029 görüntüleme • 2 yıl önce

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:
4:28

𝐁𝐫𝐢𝐠𝐡𝐭 𝐌𝐢𝐧𝐝𝐬: Dana-Farber investigators Toni Choueiri, MD and Patrick Ott describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur. Full video:

BiotechTV

13,789 görüntüleme • 1 yıl önce

📢The Phase 1/2a HEADLINE Trial of ABS-201, an AI-designed antibody for Androgenetic Alopecia (commonly known as female/male pattern hair loss) is now enrolling participants.
1:10

📢The Phase 1/2a HEADLINE Trial of ABS-201, an AI-designed antibody for Androgenetic Alopecia (commonly known as female/male pattern hair loss) is now enrolling participants.

Absci

7,275,186 görüntüleme • 21 gün önce

Rueben Bain as a senior in high school after an undefeated season. Just prior to enrolling at Miami. #hotbedworld
1:48

Rueben Bain as a senior in high school after an undefeated season. Just prior to enrolling at Miami. #hotbedworld

Brandon Odoi

41,426 görüntüleme • 2 ay önce

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.
3:23

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Dr. Misheck Ruwende

107,334 görüntüleme • 3 yıl önce

SEAN COMBS’ SEX TRAFFICKING TRIAL BEGINS: #TheView co-hosts weigh in on the high-profile trial and our Sunny Hostin details what she saw in the courtroom while attending the trial Monday.
7:35

Sensitive content

SEAN COMBS’ SEX TRAFFICKING TRIAL BEGINS: #TheView co-hosts weigh in on the high-profile trial and our Sunny Hostin details what she saw in the courtroom while attending the trial Monday.

The View

16,414 görüntüleme • 1 yıl önce

IT’S ALL A BLUR TOUR with Drizzy & Saint Laurent Don Dates now live on click the link in bio for more information and details for your location.
1:26

IT’S ALL A BLUR TOUR with Drizzy & Saint Laurent Don Dates now live on click the link in bio for more information and details for your location.

OVO Sound

2,949,859 görüntüleme • 3 yıl önce

In a landmark trial, Meta CEO Mark Zuckerberg was grilled over claims that Instagram is designed to be addictive for kids and teens. @ESchulze has details.
2:01

In a landmark trial, Meta CEO Mark Zuckerberg was grilled over claims that Instagram is designed to be addictive for kids and teens. @ESchulze has details.

World News Tonight

21,612 görüntüleme • 4 ay önce

With five cancers and a terminal diagnosis, Ben Sasse is in a clinical trial for a new drug that may be a breakthrough in pancreatic cancer treatment.
0:41

With five cancers and a terminal diagnosis, Ben Sasse is in a clinical trial for a new drug that may be a breakthrough in pancreatic cancer treatment.

60 Minutes

129,522 görüntüleme • 1 ay önce

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:
0:59

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:

PureTech

10,892 görüntüleme • 1 yıl önce

Shock New Reporting About Biden and Wheelchair, and Disturbing Diddy Trial Details, with Buck Sexton, Mark Eiglarsh, and Mark Geragos WATCH:
1:37:29

Shock New Reporting About Biden and Wheelchair, and Disturbing Diddy Trial Details, with Buck Sexton, Mark Eiglarsh, and Mark Geragos WATCH:

Megyn Kelly

107,674 görüntüleme • 1 yıl önce

🚨 The Los Angeles medical examiner ruled Celeste Rivas’ death a homicide caused by multiple penetrating injuries with unspecified objects — but key details in the autopsy report could become a major issue at trial.
3:29

🚨 The Los Angeles medical examiner ruled Celeste Rivas’ death a homicide caused by multiple penetrating injuries with unspecified objects — but key details in the autopsy report could become a major issue at trial.

TMZ

543,128 görüntüleme • 2 ay önce

In 2022, for-profit health insurers paid $10B in compensation to agents and brokers for enrolling individuals into Medicare Advantage plans. My legislation would bar financial perks for agents and brokers and ensure they work with patients to choose the best plan for them.
3:19

In 2022, for-profit health insurers paid $10B in compensation to agents and brokers for enrolling individuals into Medicare Advantage plans. My legislation would bar financial perks for agents and brokers and ensure they work with patients to choose the best plan for them.

Rep. Alexandria Ocasio-Cortez

22,235 görüntüleme • 13 gün önce

I met with a constituent who was participating in a cancer treatment trial that DOGE deemed unnecessary. I was proud to help advocate for Richard so he could resume his treatment. Cancer patients are not waste, fraud, and abuse. They're our loved ones who deserve care.
0:55

I met with a constituent who was participating in a cancer treatment trial that DOGE deemed unnecessary. I was proud to help advocate for Richard so he could resume his treatment. Cancer patients are not waste, fraud, and abuse. They're our loved ones who deserve care.

Senator Reverend Raphael Warnock

197,898 görüntüleme • 8 ay önce

Sen. Murray: You terminated a 23 year research effort to develop an HIV vaccine, just as scientists are on the cusp of a functional cure for HIV. You canceled a clinical trial evaluating new evidence-based interventions for Type 2 diabetes in Appalachia. You terminated a clinical trial to treat women with recurrent ovarian cancer. You're coming to us proposing to cut NIH funding by 40% next year. How many fewer clinical trials would you fund with a budget cut of $18 billion?
1:07

Sen. Murray: You terminated a 23 year research effort to develop an HIV vaccine, just as scientists are on the cusp of a functional cure for HIV. You canceled a clinical trial evaluating new evidence-based interventions for Type 2 diabetes in Appalachia. You terminated a clinical trial to treat women with recurrent ovarian cancer. You're coming to us proposing to cut NIH funding by 40% next year. How many fewer clinical trials would you fund with a budget cut of $18 billion?

FactPost

554,125 görüntüleme • 1 yıl önce

Elevate your game and apply to become a #BUILTAthlete today! Click the link below for more details🔥
0:24

Elevate your game and apply to become a #BUILTAthlete today! Click the link below for more details🔥

BUILT

12,762 görüntüleme • 2 yıl önce

It’s been weirdly quiet over Two Tier Keir’s Ukranian arsonist scandal. But now two of the young Ukranian models have put in a Not Guilty plea. That’s awkward for Keir as unless something changes it means it will go to trial AND all the details could come out as the defence will mount a case and call witnesses. The next hearing is at the end of November and trial scheduled for end of April. What’s the betting something mysterious stops the trial..
4:16

It’s been weirdly quiet over Two Tier Keir’s Ukranian arsonist scandal. But now two of the young Ukranian models have put in a Not Guilty plea. That’s awkward for Keir as unless something changes it means it will go to trial AND all the details could come out as the defence will mount a case and call witnesses. The next hearing is at the end of November and trial scheduled for end of April. What’s the betting something mysterious stops the trial..

JohnHann0404🇬🇧🏴󠁧󠁢󠁥󠁮󠁧󠁿

226,564 görüntüleme • 8 ay önce

With 2025 around the corner, Vagabond is wrapping up 3 years of continuous building and gearing up for a blast in the year ahead! 🎇 💠 Key milestone: Migration of VAGA to SYNNQ Get all the details in our newly published FAQ below! 👇
0:48

With 2025 around the corner, Vagabond is wrapping up 3 years of continuous building and gearing up for a blast in the year ahead! 🎇 💠 Key milestone: Migration of VAGA to SYNNQ Get all the details in our newly published FAQ below! 👇

Vagabond

26,976 görüntüleme • 1 yıl önce